Novo Nordisk Reveals P-III (REDEFINE 2) Trial data of CagriSema for Weight Loss in Obese/Overweight and T2D Patients

Shots:

• Novo Nordisk has reported P-III (REDEFINE 2) trial data assessing CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg, QW, SC) vs PBO in 1,206 obese/overweight pts (~102Kg) and type 2 diabetes for 68wks., and followed flexible dosing protocol with 61.9% pts reaching highest dose after 68wks.
• Trial met its co-1EPs demonstrated 15.7% superior weight loss vs 3.1%, while 89.7% lost ≥5% of body weight vs 30.3%. However, weight loss was 13.7% vs 3.4% using treatment policy estimand
• Additionally, Novo Nordisk has planned to file CagriSema’s first regulatory submission in Q1’26, with full REDEFINE 1 & 2 data to be presented at 2025 conferences

Ref: Novo Nordisk | Image: Novo Nordisk

Related News:-  Novo Nordisk Reveals Interim Data from P-III (FRONTIER3) Trial of Mim8 for Haemophilia A with or without Inhibitors

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com